1 Market Overview
1.1 Malignant Pleural Mesothelioma Treatment Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Malignant Pleural Mesothelioma Treatment Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Pemetrexed
1.2.3 Cisplatin
1.2.4 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Malignant Pleural Mesothelioma Treatment Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Malignant Pleural Mesothelioma Treatment Market Size & Forecast
1.4.1 Global Malignant Pleural Mesothelioma Treatment Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Malignant Pleural Mesothelioma Treatment Sales in Volume (2017-2028)
1.4.3 Global Malignant Pleural Mesothelioma Treatment Price (2017-2028)
1.5 Global Malignant Pleural Mesothelioma Treatment Production Capacity Analysis
1.5.1 Global Malignant Pleural Mesothelioma Treatment Total Production Capacity (2017-2028)
1.5.2 Global Malignant Pleural Mesothelioma Treatment Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Malignant Pleural Mesothelioma Treatment Market Drivers
1.6.2 Malignant Pleural Mesothelioma Treatment Market Restraints
1.6.3 Malignant Pleural Mesothelioma Treatment Trends Analysis
2 Manufacturers Profiles
2.1 Eli Lilly
2.1.1 Eli Lilly Details
2.1.2 Eli Lilly Major Business
2.1.3 Eli Lilly Malignant Pleural Mesothelioma Treatment Product and Services
2.1.4 Eli Lilly Malignant Pleural Mesothelioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Teva
2.2.1 Teva Details
2.2.2 Teva Major Business
2.2.3 Teva Malignant Pleural Mesothelioma Treatment Product and Services
2.2.4 Teva Malignant Pleural Mesothelioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Sanofi
2.3.1 Sanofi Details
2.3.2 Sanofi Major Business
2.3.3 Sanofi Malignant Pleural Mesothelioma Treatment Product and Services
2.3.4 Sanofi Malignant Pleural Mesothelioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Bristol-Myers Squibb
2.4.1 Bristol-Myers Squibb Details
2.4.2 Bristol-Myers Squibb Major Business
2.4.3 Bristol-Myers Squibb Malignant Pleural Mesothelioma Treatment Product and Services
2.4.4 Bristol-Myers Squibb Malignant Pleural Mesothelioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business
2.5.3 Pfizer Malignant Pleural Mesothelioma Treatment Product and Services
2.5.4 Pfizer Malignant Pleural Mesothelioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Roche
2.6.1 Roche Details
2.6.2 Roche Major Business
2.6.3 Roche Malignant Pleural Mesothelioma Treatment Product and Services
2.6.4 Roche Malignant Pleural Mesothelioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Merck
2.7.1 Merck Details
2.7.2 Merck Major Business
2.7.3 Merck Malignant Pleural Mesothelioma Treatment Product and Services
2.7.4 Merck Malignant Pleural Mesothelioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Ono Pharmaceutical
2.8.1 Ono Pharmaceutical Details
2.8.2 Ono Pharmaceutical Major Business
2.8.3 Ono Pharmaceutical Malignant Pleural Mesothelioma Treatment Product and Services
2.8.4 Ono Pharmaceutical Malignant Pleural Mesothelioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Mylan
2.9.1 Mylan Details
2.9.2 Mylan Major Business
2.9.3 Mylan Malignant Pleural Mesothelioma Treatment Product and Services
2.9.4 Mylan Malignant Pleural Mesothelioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Fresenius Kabi
2.10.1 Fresenius Kabi Details
2.10.2 Fresenius Kabi Major Business
2.10.3 Fresenius Kabi Malignant Pleural Mesothelioma Treatment Product and Services
2.10.4 Fresenius Kabi Malignant Pleural Mesothelioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Sun Pharmaceuticals
2.11.1 Sun Pharmaceuticals Details
2.11.2 Sun Pharmaceuticals Major Business
2.11.3 Sun Pharmaceuticals Malignant Pleural Mesothelioma Treatment Product and Services
2.11.4 Sun Pharmaceuticals Malignant Pleural Mesothelioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Malignant Pleural Mesothelioma Treatment Breakdown Data by Manufacturer
3.1 Global Malignant Pleural Mesothelioma Treatment Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Malignant Pleural Mesothelioma Treatment Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Malignant Pleural Mesothelioma Treatment
3.4 Market Concentration Rate
3.4.1 Top 3 Malignant Pleural Mesothelioma Treatment Manufacturer Market Share in 2021
3.4.2 Top 6 Malignant Pleural Mesothelioma Treatment Manufacturer Market Share in 2021
3.5 Global Malignant Pleural Mesothelioma Treatment Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Malignant Pleural Mesothelioma Treatment Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Malignant Pleural Mesothelioma Treatment Market Size by Region
4.1.1 Global Malignant Pleural Mesothelioma Treatment Sales in Volume by Region (2017-2028)
4.1.2 Global Malignant Pleural Mesothelioma Treatment Revenue by Region (2017-2028)
4.2 North America Malignant Pleural Mesothelioma Treatment Revenue (2017-2028)
4.3 Europe Malignant Pleural Mesothelioma Treatment Revenue (2017-2028)
4.4 Asia-Pacific Malignant Pleural Mesothelioma Treatment Revenue (2017-2028)
4.5 South America Malignant Pleural Mesothelioma Treatment Revenue (2017-2028)
4.6 Middle East and Africa Malignant Pleural Mesothelioma Treatment Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Malignant Pleural Mesothelioma Treatment Sales in Volume by Type (2017-2028)
5.2 Global Malignant Pleural Mesothelioma Treatment Revenue by Type (2017-2028)
5.3 Global Malignant Pleural Mesothelioma Treatment Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Malignant Pleural Mesothelioma Treatment Sales in Volume by Application (2017-2028)
6.2 Global Malignant Pleural Mesothelioma Treatment Revenue by Application (2017-2028)
6.3 Global Malignant Pleural Mesothelioma Treatment Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Malignant Pleural Mesothelioma Treatment Sales by Type (2017-2028)
7.2 North America Malignant Pleural Mesothelioma Treatment Sales by Application (2017-2028)
7.3 North America Malignant Pleural Mesothelioma Treatment Market Size by Country
7.3.1 North America Malignant Pleural Mesothelioma Treatment Sales in Volume by Country (2017-2028)
7.3.2 North America Malignant Pleural Mesothelioma Treatment Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Malignant Pleural Mesothelioma Treatment Sales by Type (2017-2028)
8.2 Europe Malignant Pleural Mesothelioma Treatment Sales by Application (2017-2028)
8.3 Europe Malignant Pleural Mesothelioma Treatment Market Size by Country
8.3.1 Europe Malignant Pleural Mesothelioma Treatment Sales in Volume by Country (2017-2028)
8.3.2 Europe Malignant Pleural Mesothelioma Treatment Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Malignant Pleural Mesothelioma Treatment Sales by Type (2017-2028)
9.2 Asia-Pacific Malignant Pleural Mesothelioma Treatment Sales by Application (2017-2028)
9.3 Asia-Pacific Malignant Pleural Mesothelioma Treatment Market Size by Region
9.3.1 Asia-Pacific Malignant Pleural Mesothelioma Treatment Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Malignant Pleural Mesothelioma Treatment Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Malignant Pleural Mesothelioma Treatment Sales by Type (2017-2028)
10.2 South America Malignant Pleural Mesothelioma Treatment Sales by Application (2017-2028)
10.3 South America Malignant Pleural Mesothelioma Treatment Market Size by Country
10.3.1 South America Malignant Pleural Mesothelioma Treatment Sales in Volume by Country (2017-2028)
10.3.2 South America Malignant Pleural Mesothelioma Treatment Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Malignant Pleural Mesothelioma Treatment Sales by Type (2017-2028)
11.2 Middle East & Africa Malignant Pleural Mesothelioma Treatment Sales by Application (2017-2028)
11.3 Middle East & Africa Malignant Pleural Mesothelioma Treatment Market Size by Country
11.3.1 Middle East & Africa Malignant Pleural Mesothelioma Treatment Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Malignant Pleural Mesothelioma Treatment Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Malignant Pleural Mesothelioma Treatment and Key Manufacturers
12.2 Manufacturing Costs Percentage of Malignant Pleural Mesothelioma Treatment
12.3 Malignant Pleural Mesothelioma Treatment Production Process
12.4 Malignant Pleural Mesothelioma Treatment Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Malignant Pleural Mesothelioma Treatment Typical Distributors
13.3 Malignant Pleural Mesothelioma Treatment Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
世界の悪性胸膜中皮腫治療市場2022年：ペメトレキセド、シスプラチン、その他 |
| 【英語タイトル】Global Malignant Pleural Mesothelioma Treatment Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028 | |
 | ・商品コード：GIR22NO19741 ・発行会社（調査会社）：GlobalInfoResearch ・発行日：2022年11月2日（※2025年版があります。お問い合わせください。） ・ページ数：102 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（注文後2-3日） ・調査対象地域：グローバル ・産業分野：医薬品 |
| Single User（1名様閲覧用） | USD3,480 ⇒換算￥528,960 | 見積依頼/購入/質問フォーム |
| Multi User（20名様閲覧用） | USD5,220 ⇒換算￥793,440 | 見積依頼/購入/質問フォーム |
| Corporate User（同一法人内共有可） | USD6,960 ⇒換算￥1,057,920 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| 悪性胸膜中皮腫治療市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 GlobalInfoResearchの最新の調査によると、世界の悪性胸膜中皮腫治療の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 悪性胸膜中皮腫治療市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメントは次をカバーします。 ・ペメトレキセド、シスプラチン、その他 用途別セグメントは次のように区分されます。 ・病院、診療所、その他 世界の悪性胸膜中皮腫治療市場の主要な市場プレーヤーは以下のとおりです。 ・Eli Lilly、Teva、Sanofi、Bristol-Myers Squibb、Pfizer、Roche、Merck、Ono Pharmaceutical、Mylan、Fresenius Kabi、Sun Pharmaceuticals 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、悪性胸膜中皮腫治療製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要な悪性胸膜中皮腫治療メーカーの企業概要、2019年～2022年までの悪性胸膜中皮腫治療の価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要な悪性胸膜中皮腫治療メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2017年～2028年までの地域別悪性胸膜中皮腫治療の販売量、売上、成長性を示しています。 ・第5、6章では、2017年～2028年までの悪性胸膜中皮腫治療の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での悪性胸膜中皮腫治療市場予測を収録しています。 ・第12章では、主要な原材料、主要なサプライヤー、および悪性胸膜中皮腫治療の産業チェーンを掲載しています。 ・第13、14、15章では、悪性胸膜中皮腫治療の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。 ***** 目次(一部) ***** ・市場概要 - 悪性胸膜中皮腫治療の概要 - 種類別分析（2017年vs2021年vs2028年）：ペメトレキセド、シスプラチン、その他 - 用途別分析（2017年vs2021年vs2028年）：病院、診療所、その他 - 世界の悪性胸膜中皮腫治療市場規模・予測 - 世界の悪性胸膜中皮腫治療生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - Eli Lilly、Teva、Sanofi、Bristol-Myers Squibb、Pfizer、Roche、Merck、Ono Pharmaceutical、Mylan、Fresenius Kabi、Sun Pharmaceuticals ・メーカー別市場シェア・市場集中度 ・地域別市場分析2017年-2028年 ・種類別分析2017年-2028年：ペメトレキセド、シスプラチン、その他 ・用途別分析2017年-2028年：病院、診療所、その他 ・悪性胸膜中皮腫治療の北米市場 - 種類別市場規模2017年-2028年 - 用途別市場規模2017年-2028年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・悪性胸膜中皮腫治療のヨーロッパ市場 - 種類別市場規模2017年-2028年 - 用途別市場規模2017年-2028年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・悪性胸膜中皮腫治療のアジア市場 - 種類別市場規模2017年-2028年 - 用途別市場規模2017年-2028年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・悪性胸膜中皮腫治療の南米市場 - 種類別市場規模2017年-2028年 - 用途別市場規模2017年-2028年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・悪性胸膜中皮腫治療の中東・アフリカ市場 - 種類別市場規模2017年-2028年 - 用途別市場規模2017年-2028年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Malignant Pleural Mesothelioma Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Malignant Pleural Mesothelioma Treatment market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospitals accounting for % of the Malignant Pleural Mesothelioma Treatment global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Pemetrexed segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Malignant Pleural Mesothelioma Treatment include Eli Lilly, Teva, Sanofi, Bristol-Myers Squibb, and Pfizer, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Malignant Pleural Mesothelioma Treatment market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Pemetrexed
Cisplatin
Others
Market segment by Application can be divided into
Hospitals
Clinics
Others
The key market players for global Malignant Pleural Mesothelioma Treatment market are listed below:
Eli Lilly
Teva
Sanofi
Bristol-Myers Squibb
Pfizer
Roche
Merck
Ono Pharmaceutical
Mylan
Fresenius Kabi
Sun Pharmaceuticals
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Malignant Pleural Mesothelioma Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Malignant Pleural Mesothelioma Treatment, with price, sales, revenue and global market share of Malignant Pleural Mesothelioma Treatment from 2019 to 2022.
Chapter 3, the Malignant Pleural Mesothelioma Treatment competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Malignant Pleural Mesothelioma Treatment breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Malignant Pleural Mesothelioma Treatment market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Malignant Pleural Mesothelioma Treatment.
Chapter 13, 14, and 15, to describe Malignant Pleural Mesothelioma Treatment sales channel, distributors, customers, research findings and conclusion, appendix and data source.
| ★調査レポート[世界の悪性胸膜中皮腫治療市場2022年：ペメトレキセド、シスプラチン、その他] (コード：GIR22NO19741)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界の悪性胸膜中皮腫治療市場2022年：ペメトレキセド、シスプラチン、その他]についてメールでお問い合わせ |
